What baseline anticoagulation panel should be obtained for a patient who is starting or currently receiving anticoagulant therapy?

Baseline Anticoagulation Panel

For patients starting or currently receiving anticoagulant therapy, obtain a baseline panel consisting of: CBC with platelet count, PT/INR, aPTT, and renal and hepatic function tests (creatinine clearance, transaminases, bilirubin). 1, 2

Core Laboratory Tests Required

The baseline anticoagulation panel serves two critical purposes: establishing pre-treatment values for monitoring and identifying contraindications or dose adjustments needed based on organ function.

Essential Tests for All Patients

• Complete Blood Count (CBC) with platelet count: Establishes baseline hemoglobin/hematocrit and platelet count to detect pre-existing thrombocytopenia or anemia 2
• PT/INR: Required baseline for VKA therapy and helps detect underlying coagulopathy 1
• aPTT: Essential baseline for unfractionated heparin monitoring and detects pre-existing prolongation that may complicate monitoring 3
• Renal function panel (creatinine, calculated CrCl): Critical for dose adjustment of DOACs, LMWH, and fondaparinux, particularly when CrCl <30 mL/min 2, 4
• Hepatic function tests (transaminases, bilirubin): Identifies hepatic impairment requiring dose reduction, especially for argatroban and certain DOACs 3

Anticoagulant-Specific Considerations

For Unknown Anticoagulant Status (Emergency Settings)

When anticoagulant history is unknown, measure: anti-Xa activity (UFH/LMWH calibrated), thrombin time (TT), PT/INR, and aPTT to detect or exclude any anticoagulant in plasma. 1

This comprehensive screening approach is necessary because:

• PT/INR alone detects VKA but inconsistently detects DOACs
• aPTT detects UFH and dabigatran but is insensitive to LMWH and fondaparinux
• TT is highly sensitive to dabigatran and UFH but not to anti-Xa agents
• Anti-Xa activity detects LMWH, fondaparinux, and anti-Xa DOACs 1

For Known Anticoagulant Type

When the specific anticoagulant is known, tailor testing to the agent:

• VKA (warfarin): PT/INR or point-of-care INR 1
• UFH/LMWH/fondaparinux: Anti-Xa activity with appropriate calibration 1
• DOACs: Drug-specific concentration measurement (not routine coagulation tests) 1
• Argatroban: aPTT must be measured before treatment to establish baseline, as pre-existing prolongation (common in ICU, post-cardiac surgery, liver failure) may preclude its use for monitoring 3

Monitoring Frequency After Initiation

Following anticoagulant initiation, monitor hemoglobin, hematocrit, and platelet count every 2-3 days for the first 14 days in inpatients, then every 2 weeks or as clinically indicated. 2

This frequent early monitoring detects:

• Occult bleeding (declining hemoglobin/hematocrit)
• Heparin-induced thrombocytopenia (HIT) - typically develops 5-10 days after heparin exposure
• Over-anticoagulation effects

Common Pitfalls to Avoid

1. Do not use viscoelastometric tests (VET) to screen for anticoagulants or assess anticoagulation level - these tests lack sensitivity and specificity for this purpose 1

2. Do not rely on PT/INR and aPTT alone to exclude DOACs - these tests are inconsistently affected by DOACs and cannot reliably rule out their presence 1, 5, 1

3. Do not skip renal function testing - this is the most critical factor for dose adjustment of DOACs and LMWH, with major bleeding risk when CrCl <30 mL/min 2, 4

4. For argatroban monitoring, do not accept aPTT >100 seconds as target - maintain target well below 100 seconds to reduce bleeding risk, and consider alternative tests (ecarin clotting time, diluted thrombin time) if baseline aPTT is already prolonged 3

5. In obese patients (BMI ≥30), calculate initial anticoagulant doses on actual body weight and consider anti-Xa monitoring for LMWH at extremes of weight 3, 6

Special Populations Requiring Modified Panels

• Cancer patients: Same baseline panel, but recognize higher bleeding and thrombosis risk; DOACs and LMWH preferred over warfarin 7, 2
• Severe renal impairment (CrCl <30 mL/min): Avoid or dose-reduce DOACs and LMWH; UFH or warfarin may be preferred 2, 4
• Severe hepatic impairment (Child-Pugh C): Argatroban contraindicated; reduce initial dose by 75% for Child-Pugh B 3